Nothing Special   »   [go: up one dir, main page]
create a website
Pricing dynamics and product quality: the case of antidepressant drugs. (2012). Rizzo, John ; Chen, Jie.
In: Empirical Economics.
RePEc:spr:empeco:v:42:y:2012:i:1:p:279-300.

Full description at Econpapers || Download paper

Cited: 4

Citations received by this document

Cites: 56

References cited by this document

Cocites: 50

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Foreign direct investment and product quality in host economies. (2023). Sun, Sizhong ; Anwar, Sajid.
    In: The World Economy.
    RePEc:bla:worlde:v:46:y:2023:i:5:p:1290-1318.

    Full description at Econpapers || Download paper

  2. Estimation of product quality in Chinas food processing and manufacturing industries. (2022). Anwar, Sajid ; Sun, Sizhong.
    In: Economic Modelling.
    RePEc:eee:ecmode:v:107:y:2022:i:c:s0264999321002704.

    Full description at Econpapers || Download paper

  3. Differentiation strategies in agribusiness – A configurational approach. (2020). Acua, Joseph ; Ciravegna, Luciano ; Brenes, Esteban R.
    In: Journal of Business Research.
    RePEc:eee:jbrese:v:119:y:2020:i:c:p:522-539.

    Full description at Econpapers || Download paper

  4. Pricing in the Market for Anticancer Drugs. (2015). Howard, David H. ; Conti, Rena M. ; Bach, Peter B. ; Berndt, Ernst R..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:20867.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Allan M, Innes G (2004) Do family physicians know the costs of medical care?. Can Fam Physician 50: 263–270.
    Paper not yet in RePEc: Add citation now

  2. Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence. J Econ Manag Strat 11: 551–594.

  3. Bagwell K, Riordan M (1991) High and declining prices signal product quality. Am Econ Rev 81: 224–239.

  4. Bergemann D, Valimaki J (2006) Dynamic pricing of new experience goods. J Polit Econ 114: 713–743.

  5. Berndt E, Bhattacharjya A, Mishol D et al (2002) An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy Econ 5: 3–19.
    Paper not yet in RePEc: Add citation now

  6. Berndt E, Cockburn I, Griliches Z (1996) Pharmaceutical innovations and market dynamics: tracking effects on price indexes for anti-depressant drugs. Brookings Pap Econ Act 133–188.

  7. Berndt ER, Kyle MK, Ling D (2003) The long shadow of patent expiration: generic entry and rx to OTC switches. http://www.nber.org/chapters/c9737.pdf . Accessed 5 Aug 2010.

  8. Bhattacharya J, Vogt W (2003) A simple model of pharmaceutical price dynamics. J Law Econ 46: 599–626.

  9. Caves R, Whinston M, Hurwitz M (1991) Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Pap Econ Act 3–65.
    Paper not yet in RePEc: Add citation now

  10. Ching A, Ishihara M (2007) The effects of detailing on prescribing decisions under two-sided learning. MPAR Paper No. 1935.

  11. Cohen J (1997) Sample design of the 1996 medical expenditure panel survey household component MEPS methodology report No. 2. AHCPR Pub. No. 97-0027. Agency for Health Care Policy and Research, Rockville.
    Paper not yet in RePEc: Add citation now

  12. Comanor W (1986) The political economy of the pharmaceutical industry. J Econ Lit XXIV: 1178–1217.

  13. Congressional Budget Office: (1998) How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry?. Congressional Budget Office, Washington.
    Paper not yet in RePEc: Add citation now
  14. Conti G, Dell’Utri D, Pelaia P et al (1998) Do we know the costs of what we prescribe? A study on awareness of the costs of drugs and devices among ICU Staff. Intensive Care Med 24: 1194–1198.
    Paper not yet in RePEc: Add citation now

  15. Dean J (1969) Pricing pioneering products. J Ind Econ 17: 165–179.

  16. Dolan R, Jeuland A (1981) Experience curves and dynamic demand models: implications for optimal pricing strategies. J Mark 45: 52–62.
    Paper not yet in RePEc: Add citation now
  17. Donohue J, Berndt E (2004) Effects of direct-to-consumer advertising on medication choice: the case of antidepressants. J Public Pol Mark 23: 115–127.
    Paper not yet in RePEc: Add citation now
  18. Drug Benefit Trends (2005) More Americans take prescription medication. Trend Month 17:55.
    Paper not yet in RePEc: Add citation now

  19. Eaton B, Lipsey R (1989) Product differentiation. Handbook of Industrial Organization, North Holland.

  20. Ellison S, Cockburn I, Griliches Z et al (1997) Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. Rand J Econ 28: 426–446.

  21. Ellison SF, Ellison G (2007) Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration: working paper No. 13069. http://www.nber.org/papers/w13069 . Accessed date 16 Nov 2009.

  22. Feldstein P (2009) Health policy issues an economic perspective, 4th ed. HAP.,.
    Paper not yet in RePEc: Add citation now

  23. Frank R, Salkever D (1997) Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy 6: 75–90.

  24. Glickman L, Bruce E, Caro F et al (1994) Physicians’ knowledge of drug costs for the elderly. J Am Geriatr Soc 42: 992–996.
    Paper not yet in RePEc: Add citation now

  25. Grabowski H, Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 35: 331–350.

  26. Greenberg P, Kessler R, Birnbaum H et al (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000. J Clin Psychiatry 64: 1465–1476.
    Paper not yet in RePEc: Add citation now
  27. Greene W (1999) Econometric analysis, 4th ed. Prentice Hall International, Inc., Upper Saddle River.
    Paper not yet in RePEc: Add citation now

  28. Grossman G, Shapiro C (1984) Informative advertising with differentiated products. Rev Econ Stud 5(1): 63–81.

  29. Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J Law Econ 31: 299–320.

  30. Huskamp H, Donohue JM, Koss C et al (2008) Generic entry, reformulations and promotion of ssris in the US. Pharmacoeconomics 26: 603–616.

  31. Iizuka T (2004) What explains the use of DTCA of prescription drugs. J Ind Econ 52: 349–379.
    Paper not yet in RePEc: Add citation now
  32. Kaiser Family Foundation (2005) Prescription drug trends. http://www.kff.org/insurance/upload/3057-04.pdf . Accessed 30 Nov 2006.
    Paper not yet in RePEc: Add citation now
  33. Kaiser Family Foundation (2007) Prescription drug trends fact sheet. http://www.kff.org/rxdrugs/upload/3057_06.pdf . Accessed 10 Oct 2008.
    Paper not yet in RePEc: Add citation now
  34. Kaiser Family Foundation (2008) Employee health benefits 2008 annual survey. http://ehbs.kff.org/?page=charts&id=1&sn=8&p=1 . Accessed Feb 2009.
    Paper not yet in RePEc: Add citation now
  35. Katon W, Sullivan M (1990) Depression and chronic medical illness. J Clin Psychiatry 51: 3–11.
    Paper not yet in RePEc: Add citation now
  36. Kessler R, McGonagle K, Swartz M et al (1993) Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 29: 85–96.
    Paper not yet in RePEc: Add citation now
  37. Kessler R, McGonagle K, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.
    Paper not yet in RePEc: Add citation now
  38. Langman M, Kahler KH, Kong SX et al (2001) Drug Switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 10: 517–524.
    Paper not yet in RePEc: Add citation now

  39. Lu J, Comanor W (1998) Strategic pricing of new pharmaceuticals. Rev Econ Stat 80: 108–118.

  40. Meyerhoefer C, Zuvekas S (2008) The shape of demand: what does it tell us about direct-to-consumer advertising of antidepressants. B.E. J Econom Anal Policy 8:4.

  41. Pomerantz JM (2003) Antidepressants used as placebos: is that good practice? MedScape report. http://www.medscape.com/viewarticle/461430 . Accessed date 10 Feb 2009.
    Paper not yet in RePEc: Add citation now

  42. Rao V (1984) Pricing research in marketing: the state of the art. J Bus 57: 39–64.

  43. Reekie D (1978) Price and quality competition in the United States drug industry. J Ind Econ 26: 223–237.

  44. Rizzo J (1999) Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. J Law Econ 42: 89–116.

  45. Santerre R, Neun S (2009) Health economics: theory, insights, and industry studies, 5th edn. South-Western College Publication, Madson.
    Paper not yet in RePEc: Add citation now

  46. Schmalensee R (1982) Product differentiation advantages of pioneering brands. Am Econ Rev 72: 349–365.

  47. Shapiro C (1983) Optimal pricing of experience goods. Bell J Econ 14: 497–507.

  48. Shrank W, Ettner S, Glassman P et al (2004) A bitter pill: formulary variability and the challenge to prescribing physicians. J Am Board Fam Pract 17: 401–407.
    Paper not yet in RePEc: Add citation now
  49. Silcock J, Ryan M, Bond CM et al (1997) The cost of medicines in the United Kingdom: A survey of general practitioners’ opinions and knowledge. Pharmacoeconomics 11: 56–63.
    Paper not yet in RePEc: Add citation now
  50. Thase M (1990) Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry 51: 51–57.
    Paper not yet in RePEc: Add citation now
  51. Wilk JE, West JC, Rae DS et al (2006) Patterns of adult psychotherapy in psychiatric practice. Psychiatr Serv 57: 472–476.
    Paper not yet in RePEc: Add citation now
  52. Woods S, Rizzo J (1997) Cost effectiveness of antidepressant treatment revisited. Br J Psychiatry 170: 257–263.
    Paper not yet in RePEc: Add citation now
  53. Wooldridge J (1999) Introductory econometrics: a modern approach. South-Western Publication, Cincinnati.
    Paper not yet in RePEc: Add citation now

  54. Wooldridge J (2001) Econometric analysis of cross section and panel data, 1st edn. The MIT Press, Boston.

  55. Zhao S, Wentworth C, Burke T et al (2004) Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 13: 277–287.
    Paper not yet in RePEc: Add citation now
  56. Zuvekas S (2005) Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff 24: 195–205.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Do Firms Publish? A Multi-Sectoral Analysis. (2018). Rotolo, Daniele ; Grassano, Nicola ; Camerani, Roberto.
    In: SPRU Working Paper Series.
    RePEc:sru:ssewps:2018-21.

    Full description at Econpapers || Download paper

  2. Do firms publish? A multi-sectoral analysis. (2018). Rotolo, Daniele ; Grassano, Nicola ; Camerani, Roberto.
    In: JRC Working Papers on Corporate R&D and Innovation.
    RePEc:ipt:wpaper:201805.

    Full description at Econpapers || Download paper

  3. Knowledge dissemination in clinical trials: Exploring influences of institutional support and type of innovation on selective reporting. (2018). Salandra, Rossella.
    In: Research Policy.
    RePEc:eee:respol:v:47:y:2018:i:7:p:1215-1228.

    Full description at Econpapers || Download paper

  4. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Discussion Paper.
    RePEc:tiu:tiutil:be3f3c38-5e39-4a67-af57-820c14957e0b.

    Full description at Econpapers || Download paper

  5. Umbrella Branding in Pharmaceutical Markets. (2017). Suppliet, Moritz.
    In: Discussion Paper.
    RePEc:tiu:tiucen:6ee607fc-8602-4270-a076-3b0a18f71366.

    Full description at Econpapers || Download paper

  6. How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry. (2016). Park, Gunno ; Ji, Sang ; Shin, Kwangsoo.
    In: Asia Pacific Journal of Management.
    RePEc:kap:asiapa:v:33:y:2016:i:1:d:10.1007_s10490-015-9439-7.

    Full description at Econpapers || Download paper

  7. Corporate Science, Innovation, and Firm Value. (2016). Cincera, Michele ; Simeth, Markus .
    In: Management Science.
    RePEc:inm:ormnsc:v:62:y:2016:i:7:p:1970-1981.

    Full description at Econpapers || Download paper

  8. Brand Performance Volatility from Marketing Spending. (2016). Shin, Hyun Song ; Fischer, Marc ; Hanssens, Dominique M.
    In: Management Science.
    RePEc:inm:ormnsc:v:62:y:2016:i:1:p:197-215.

    Full description at Econpapers || Download paper

  9. The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs. (2016). Horstmann, Ignatius ; Clark, Robert ; Ching, Andrew ; Lim, Hyunwoo.
    In: Marketing Science.
    RePEc:inm:ormksc:v:35:y:2016:i:1:p:158-181.

    Full description at Econpapers || Download paper

  10. Killing the Golden Goose? The Decline of Science in Corporate R&D. (2015). Belenzon, Sharon ; Arora, Ashish ; Patacconi, Andrea.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:20902.

    Full description at Econpapers || Download paper

  11. How do firms develop capabilities for scientific disclosure?. (2015). Lhuillery, Stephane ; Simeth, Markus .
    In: Research Policy.
    RePEc:eee:respol:v:44:y:2015:i:7:p:1283-1295.

    Full description at Econpapers || Download paper

  12. The Regulation of Direct-to-Consumer Advertising of Pharmaceuticals in a Managed Care Setting. (2015). Ryan, Matthew ; Vaithianathan, Rhema .
    In: Journal of Public Economic Theory.
    RePEc:bla:jpbect:v:17:y:2015:i:6:p:986-1021.

    Full description at Econpapers || Download paper

  13. The commercial contribution of clinical studies for pharmaceutical drugs. (2014). Sood, Ashish ; Stremersch, Stefan ; Kappe, Eelco.
    In: International Journal of Research in Marketing.
    RePEc:eee:ijrema:v:31:y:2014:i:1:p:65-77.

    Full description at Econpapers || Download paper

  14. Information technology and agency in physicians prescribing decisions. (2014). Epstein, Andrew J. ; Ketcham, Jonathan D..
    In: RAND Journal of Economics.
    RePEc:bla:randje:v:45:y:2014:i:2:p:422-448.

    Full description at Econpapers || Download paper

  15. Pharmaceutical Followers. (2013). Ridley, David ; Ellickson, Paul ; Landry, Peter ; Arcidiacono, Peter .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19522.

    Full description at Econpapers || Download paper

  16. What is the value of ‘me-too’ drugs?. (2013). Regnier, Stephane .
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:16:y:2013:i:4:p:300-313.

    Full description at Econpapers || Download paper

  17. Pharmaceutical advertising and Medicare Part D. (2013). Sood, Neeraj ; Lakdawalla, Darius ; Gu, Qian .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:32:y:2013:i:6:p:1356-1367.

    Full description at Econpapers || Download paper

  18. Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?. (2013). Siotis, Georges ; Ornaghi, Carmine ; de Frutos, Maria-Angeles .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:32:y:2013:i:1:p:268-285.

    Full description at Econpapers || Download paper

  19. Drug withdrawals and the utilization of therapeutic substitutes: The case of Vioxx. (2013). Simon, Kosali I. ; Tennyson, Sharon ; Collins, Michael J..
    In: Journal of Economic Behavior & Organization.
    RePEc:eee:jeborg:v:86:y:2013:i:c:p:148-168.

    Full description at Econpapers || Download paper

  20. Pharmaceutical followers. (2013). Ridley, David ; Landry, Peter ; Arcidiacono, Peter ; Ellickson, Paul B..
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:5:p:538-553.

    Full description at Econpapers || Download paper

  21. Informing the uninformed: How drug advertising affects check-up visits. (2013). Wendling, Brett ; Hosken, Daniel .
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:2:p:181-194.

    Full description at Econpapers || Download paper

  22. The impact of scientific research on health care: Evidence from the OECD countries. (2013). Moscone, Francesco ; Tosetti, Elisa ; Costantini, Marco ; Ali, Maged .
    In: Economic Modelling.
    RePEc:eee:ecmode:v:32:y:2013:i:c:p:325-332.

    Full description at Econpapers || Download paper

  23. Pricing dynamics and product quality: the case of antidepressant drugs. (2012). Rizzo, John ; Chen, Jie.
    In: Empirical Economics.
    RePEc:spr:empeco:v:42:y:2012:i:1:p:279-300.

    Full description at Econpapers || Download paper

  24. Physician response to financial incentives when choosing drugs to treat breast cancer. (2012). Johnson, Scott ; Epstein, Andrew .
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:12:y:2012:i:4:p:285-302.

    Full description at Econpapers || Download paper

  25. Getting Competition Down to a Science: The Effects of Technological Competition on Firms Scientific Publications. (2012). Polidoro, Francisco ; Theeke, Matt .
    In: Organization Science.
    RePEc:inm:ororsc:v:23:y:2012:i:4:p:1135-1153.

    Full description at Econpapers || Download paper

  26. The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications. (2011). Liu, Qiang ; Gupta, Sachin.
    In: International Journal of Research in Marketing.
    RePEc:eee:ijrema:v:28:y:2011:i:3:p:205-217.

    Full description at Econpapers || Download paper

  27. Does Patient Use of Medical Information Affect Physician Practice Incentives to Provide Care?. (2011). Rizzo, John ; Fang, Hai .
    In: Forum for Health Economics & Policy.
    RePEc:bpj:fhecpo:v:14:y:2011:i:2:n:2.

    Full description at Econpapers || Download paper

  28. The effects of detailing on prescribing decisions under quality uncertainty. (2010). Ching, Andrew ; Ishihara, Masakazu.
    In: Quantitative Marketing and Economics (QME).
    RePEc:kap:qmktec:v:8:y:2010:i:2:p:123-165.

    Full description at Econpapers || Download paper

  29. Deviation Among Technology Reviews: An Informative Enrichment of Technology Evolution Theory for Marketing. (2010). Stremersch, Stefan ; Sood, A..
    In: ERIM Report Series Research in Management.
    RePEc:ems:eureri:17766.

    Full description at Econpapers || Download paper

  30. Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?. (2010). Siotis, Georges ; Ornaghi, Carmine ; de Frutos, Maria-Angeles.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:8076.

    Full description at Econpapers || Download paper

  31. Incentives for clinical trials. (2009). Grönqvist, Erik ; Lundin, Douglas ; Gronqvist, Erik.
    In: Economics of Innovation and New Technology.
    RePEc:taf:ecinnt:v:18:y:2009:i:5:p:513-531.

    Full description at Econpapers || Download paper

  32. Information, learning, and drug diffusion: The case of Cox-2 inhibitors. (2009). Chintagunta, Pradeep ; Jiang, Renna ; Jin, Ginger.
    In: Quantitative Marketing and Economics (QME).
    RePEc:kap:qmktec:v:7:y:2009:i:4:p:399-443.

    Full description at Econpapers || Download paper

  33. Knowledge and information flows in supply chains: A study on pharmaceutical companies. (2009). Nakano, Davi ; Pedroso, Marcelo Caldeira .
    In: International Journal of Production Economics.
    RePEc:eee:proeco:v:122:y:2009:i:1:p:376-384.

    Full description at Econpapers || Download paper

  34. Patient education and the impact of new medical research. (2009). Simon, Kosali ; Price, Joseph.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:28:y:2009:i:6:p:1166-1174.

    Full description at Econpapers || Download paper

  35. Trials, tricks and transparency: How disclosure rules affect clinical knowledge. (2009). Porteiro, Nicolás ; González, Paula ; Dahm, Matthias ; Gonzalez, Paula.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:28:y:2009:i:6:p:1141-1153.

    Full description at Econpapers || Download paper

  36. Trials, tricks and transparency: how disclosure rules affect clinical knowledge. (2008). González, Paula ; Dahm, Matthias ; Gonzalez, Paula ; Fresco, Nicolas Porteiro .
    In: Working Papers.
    RePEc:urv:wpaper:2072/5360.

    Full description at Econpapers || Download paper

  37. Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge. (2008). Porteiro, Nicolás ; González, Paula ; Dahm, Matthias ; Gonzalez, Paula.
    In: Working Papers.
    RePEc:pab:wpaper:08.02.

    Full description at Econpapers || Download paper

  38. Generalizations on the effectiveness of pharmaceutical promotional expenditures. (2008). , Sara ; Wieringa, Jaap E ; PEter, .
    In: International Journal of Research in Marketing.
    RePEc:eee:ijrema:v:25:y:2008:i:4:p:234-246.

    Full description at Econpapers || Download paper

  39. The Effects of Detailing on Prescribing Decisions under Two-Sided Learning. (2007). Ching, Andrew ; Ishihara, Masakazu.
    In: MPRA Paper.
    RePEc:pra:mprapa:4935.

    Full description at Econpapers || Download paper

  40. The Debate on Influencing Doctors Decisions: Are Drug Characteristics the Missing Link?. (2007). Venkataraman, Sriram ; Stremersch, Stefan .
    In: Management Science.
    RePEc:inm:ormnsc:v:53:y:2007:i:11:p:1688-1701.

    Full description at Econpapers || Download paper

  41. The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link?. (2007). Stremersch, Stefan ; Venkataraman, S..
    In: ERIM Report Series Research in Management.
    RePEc:ems:eureri:10520.

    Full description at Econpapers || Download paper

  42. Incentives for Clinical Trials. (2006). Grönqvist, Erik ; Lundin, Douglas ; Gronqvist, Erik.
    In: SSE/EFI Working Paper Series in Economics and Finance.
    RePEc:hhs:hastef:0636.

    Full description at Econpapers || Download paper

  43. Direct to consumer advertising in pharmaceutical markets. (2006). Kuhn, Michael ; Brekke, Kurt.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:25:y:2006:i:1:p:102-130.

    Full description at Econpapers || Download paper

  44. The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply. (2005). DiMasi, Joseph ; Paquette, Cherie .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:23:y:2005:i:12:p:1193-1202.

    Full description at Econpapers || Download paper

  45. The Competitive Effects of Drug Withdrawals. (2005). Rizzo, John ; Cawley, John.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:11223.

    Full description at Econpapers || Download paper

  46. Direct to Consumer Advertising in Pharmaceutical Markets. (2005). Kuhn, Michael ; Brekke, Kurt.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_1493.

    Full description at Econpapers || Download paper

  47. Are Physicians ÜEasy MarksÝ? Quantifying the Effects of Detailing and Sampling on New Prescriptions. (2004). Mizik, Natalie ; Jacobson, Robert .
    In: Management Science.
    RePEc:inm:ormnsc:v:50:y:2004:i:12:p:1704-1715.

    Full description at Econpapers || Download paper

  48. An empirical model of learning and patient spillovers in new drug entry. (2004). Shum, Matthew ; Coscelli, Andrea .
    In: Journal of Econometrics.
    RePEc:eee:econom:v:122:y:2004:i:2:p:213-246.

    Full description at Econpapers || Download paper

  49. Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs. (2002). Winston, Clifford ; Stempski, Randolph ; Calfee, John E..
    In: Journal of Law and Economics.
    RePEc:ucp:jlawec:doi:10.1086/374704.

    Full description at Econpapers || Download paper

  50. Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry. (). Kryukov, Yaroslav .
    In: GSIA Working Papers.
    RePEc:cmu:gsiawp:-1122776787.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-02-01 12:53:46 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.